FPGS

Folylpolyglutamate synthase, mitochondrial · Q05932 · FPGS on Sugi Atlas →

3,383 patent compounds predicted against FPGS, 2,956 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6671573	0.42	6/20
SCHEMBL2222227	0.65	5/20
SCHEMBL6018843	0.35	4/20
Methotrexate (SCHEMBL3711)	1.00	3/20
Methotrexate (SCHEMBL3712)	1.00	3/20
Methotrexate (SCHEMBL171251)	1.00	3/20
Methotrexate (SCHEMBL2301949)	1.00	3/20
Methotrexate (SCHEMBL4136)	0.98	3/20
Methotrexate (SCHEMBL406878)	0.98	3/20
Methotrexate (SCHEMBL947898)	0.98	3/20
Methotrexate (SCHEMBL947900)	0.98	3/20
Methotrexate (SCHEMBL1000841)	0.98	3/20
Methotrexate (SCHEMBL1230252)	0.98	3/20
Methotrexate (SCHEMBL1230258)	0.98	3/20
Methotrexate (SCHEMBL1830706)	0.98	3/20
Methotrexate (SCHEMBL4399585)	0.98	3/20
Methotrexate (SCHEMBL4399588)	0.98	3/20
Methotrexate (SCHEMBL4541811)	0.98	3/20
Methotrexate (SCHEMBL5307856)	0.98	3/20
Methotrexate (SCHEMBL5313424)	0.98	3/20

Clinical trials — most relevant to FPGS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients	PHASE4	COMPLETED
TAKE TIME Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM	PHASE4	COMPLETED
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis	PHASE2	COMPLETED
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes	PHASE2	RECRUITING
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study	PHASE2	UNKNOWN
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma	PHASE2	UNKNOWN
The KHENERGY Study	PHASE2	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524	nan	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization	nan	COMPLETED
Clinical Study of Hydroxytyrosol (HT) in Mitochondrial Diseases	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Diabetic Cardiomyopathy and Heart Failure	nan	WITHDRAWN
Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells	nan	RECRUITING
C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer	nan	UNKNOWN
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD	nan	NOT_YET_RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort	nan	RECRUITING
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer	nan	COMPLETED
Metabolomic Analysis of Body Fluid of Medulloblastoma in Children	nan	UNKNOWN
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FPGS binder may also engage these)

Protein	Name	Similarity
A6H751	—	1.000	A6H751 →
P48760	—	1.000	P48760 →
Q924L9	—	0.997	Q924L9 →
ENGASE	Cytosolic endo-beta-N-acetylglucosaminidase	0.982	landscape →
Q3SYT1	—	0.980	Q3SYT1 →
Q68DD2	—	0.980	Q68DD2 →
Q9ESK3	—	0.979	Q9ESK3 →
Q91ZJ0	—	0.979	Q91ZJ0 →
Q9Z2E3	—	0.979	Q9Z2E3 →
P54777	—	0.978	P54777 →
A0A8C2MDK8	—	0.978	A0A8C2MDK8 →
E9QAM5	—	0.978	E9QAM5 →
FLAD1	FAD synthase	0.978	landscape →
Q8VDP3	—	0.978	Q8VDP3 →
Q8C9A2	—	0.977	Q8C9A2 →
A7E3S5	—	0.977	A7E3S5 →
Q5RKI3	—	0.976	Q5RKI3 →
ERN2	Serine/threonine-protein kinase/endoribonuclease IRE2	0.976	landscape →
P0C7A1	—	0.976	P0C7A1 →
Q9QXE2	—	0.976	Q9QXE2 →
Q91W34	—	0.976	Q91W34 →
O75064	—	0.976	O75064 →
Q9HC96	—	0.976	Q9HC96 →
D3ZBP4	—	0.976	D3ZBP4 →
A7YY46	—	0.975	A7YY46 →
Q8TDZ2	—	0.975	Q8TDZ2 →
Q9CWD3	—	0.975	Q9CWD3 →
Q9BZG8	—	0.975	Q9BZG8 →
PIGO	GPI ethanolamine phosphate transferase 3, catalytic subunit	0.975	landscape →
Q643R3	—	0.975	Q643R3 →